AUTL — Autolus Therapeutics plc American Depositary Share
XNAS · Healthcare · Biotechnology
Price$1.87
Market Cap$497.7M
P/E—
52W Range$1.18 – $2.70
Next Earnings2026-08-11
About Autolus Therapeutics plc American Depositary Share
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.